by Osteogenesis imperfecta (OI) also known as brittle bone disease is a rare genetic disorder characterized by bones that break easily, often from little or no apparent cause. OI is caused by mutations in genes that control collagen production. Collagen provides strength and structure in bones and other connective tissues such as skin and ligaments. Mutations in the collagen-encoding genes disrupts the normal production of collagen in the body. This leads to fragile bones that break easily due to minor stress or even from ordinary daily activities. Current treatment options for OI include bisphosphonates which help increase bone mass and reduce fractures. Other treatment options include teriparatide injections, physical therapy and braces to provide mobility and prevent fractures. The rising awareness about osteogenesis imperfecta and availability of various treatment options are fueling the growth of the global osteogenesis imperfecta treatment market.
The global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 722.8 Mn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Key Trends:
One of the major trends in the osteogenesis imperfecta treatment market is increasing research activity for development of novel therapeutics. Despite availability of current treatment options like bisphosphonates and teriparatide injections, there remains significant unmet need for more effective therapies to improve symptoms and quality of life for patients suffering from OI. Companies are investing heavily in research and development of gene therapies, monoclonal antibodies and small molecule drugs that target specific pathways involved in the pathology of OI. For instance, BioSenic SA is developing BPS-804, an anti-sclerostin monoclonal antibody currently in phase 2 trials. If approved, BPS-804 has potential to become first disease-modifying treatment for OI. Similarly, Mereo Biopharma is evaluating BPS-818, a monoclonal antibody targeting activin A in phase 1/2 clinical trials for OI. Increasing pipeline of novel drugs can significantly boost the osteogenesis imperfecta treatment market over the forecast period.
Porter’s Analysis
Threat of new entrants: Low barriers to entry as companies can leverage existing technology and distribution to enter the market. However, established brands and need for regulatory approvals pose entry barriers.
Bargaining power of buyers: Moderate, as few existing treatment options increase customer dependence on key players.
Bargaining power of suppliers: Moderate, as suppliers of core technologies and raw materials wield bargaining power.
Threat of new substitutes: Low, as no major substitute exists for treating osteogenesis imperfecta currently.
Competitive rivalry: High, as major players compete on treatment innovation, pricing and branding.
Key Takeaways
The Global Osteogenesis Imperfecta Treatment Market Size is expected to witness high growth. The global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 722.8 Mn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030.
Regional analysis
North America dominates the market currently due to high adoption of new treatments. However, Asia Pacific is expected to witness fastest growth over the forecast period driven by rising patient numbers and improving access to healthcare in countries like China and India.
Key players
Key players operating in the osteogenesis imperfecta treatment market are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp. Rising investments by these players to develop novel therapies will propel market growth.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
